ImmunityBio, Inc.
Financials
Valuation Metrics
ImmunityBio, Inc.'s Market Cap is $8.32B. At end of 2025 it was $1.96B. Ranked #981 of 3,118 in US market (top 31%), #315 of 1,474 on NASDAQ (top 21%), #51 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.32B | US#981/3,118 Sec#51/265 |
| Revenue | $166M | US#2,584/3,118 Sec#114/265 |
| Net Income | $-992M | US—/3,118 Sec—/265 |
| Total Assets | $629M | US#2,675/3,118 Sec#139/265 |
| Net Assets | $-1.05B | US#3,036/3,118 Sec#262/265 |
| Employees | 688 | US#2,133/3,118 Sec#70/265 |
| Value | ||
| P/S | 50.16x | US#2,920/3,118 Sec#167/265 |
| FCF Yield | -4.40% | US—/3,118 Sec—/265 |
| Profitability | ||
| Op. Margin | -151.88% | US#2,731/3,118 Sec#129/265 |
| Revenue Growth | 192.92% | US#55/3,118 Sec#21/265 |
| Financial Health | ||
| Total Debt | $813M | US#1,632/3,118 Sec#48/265 |
| FCF | $-366M | US#2,868/3,118 Sec#244/265 |
| Cash | $76M | US#2,376/3,118 Sec#196/265 |
| Current Ratio | 5.72x | US#408/3,118 Sec#127/265 |
| Performance | ||
| 1Y Return | 230.83% | US#23/3,118 Sec#9/265 |
| 1M Return | -22.84% | US#2,545/3,118 Sec#190/265 |
| From 52W High | -36.12% | US#2,093/3,118 Sec#137/265 |
| 1Y MDD | -42.34% | US#2,036/3,118 Sec#130/265 |
| Trading | ||
| Volume | 8,150,774 shares | US#218/3,118 Sec#11/265 |
| Trading Value | $66M | US#1,047/3,118 Sec#61/265 |
| Per Share | ||
| EPS | $-0.95 | US—/3,118 Sec—/265 |
| BPS | $-1.00 | US—/3,118 Sec—/265 |
Company Info
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.